Headquartered in Tucson, Arizona, HTG is focused on accelerating precision medicine – from diagnosis to treatment – by harnessing the power of transcriptome-wide profiling to drive translational research, clinical diagnostics and targeted therapeutics across a variety of disease areas. HTG’s proprietary extraction-free RNA expression technology simplifies and automates complex, highly multiplexed gene expression profiling from solid and (biofluid) liquid samples, even when limited by amount and quality. HTG’s transcriptome and targeted panels are designed to enable biomarker profile assessment and gene signature development associated with disease state, treatment response and outcome.
We are a CRO specialising in the analysis of proteins and their associated PTM’s via advanced Mass Spectrometry. By using proprietary methodologies, we can detect up to 8,000 proteins per sample in Discovery mode and can offer multiplexed assays of up to 100 proteins/sample in a GCLP accredited Targeted assay.
With their proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up-, or down-regulated with disease progression or drug treatment.
We offer SomaScan Discovery, a 7,000 target proteomic analysis tool, which is used in a range of applications from biomarker discovery to target validation, as well as a variety of uses in clinical trials. We also offer SomaSignal Tests, proteomic signatures trained against clinical outcomes. Currently there is a menu of 20 tests with a robust pipeline. SomaScan Discovery and SomaSignal Tests are all available from a single blood draw.
.png)
Randox Laboratories has established itself as a leading diagnostics developer for laboratories of all sizes. Our Qnostics' molecular IQC portfolio caters to the diverse needs of molecular diagnostics and Nucleic Acid Testing (NAT) laboratories. With a wide range of viral, bacterial, and fungal targets, it ensures precise and reliable testing, boosting lab performance and result confidence.
Randox Qnostics' molecular IQC portfolio guarantees accurate outcomes, empowering labs worldwide.
For more information, visit www.randox.com or contact [email protected].
Cura Diagnostics, LLC (iCura) is a fast-growing Contract Research Orgnization (CRO) and Clinical Diagnostics Laboratory, conveniently located in the tri-state area of Pennsylvania (adjacent to New Jersey and Delaware). iCura Diagnostics has focused its services on utilizing advanced diagnostic technologies such as Digital Pathology, multiplexing Immunofluorescence (IF)/Immunohistochemistry (IHC), Digital Image Analysis, Liquid Biopsy (including Circulating Tumor Cells (CTC) and ctDNA), and Genomic Services ranging from realtime PCR, digital PCR, to NGS, to provide translational research services, as well as clinical diagnostic services for oncology, metabolic disease, neurologic disorder, cardiovascular conditions, etc. The technology and services provided by iCura can be widely applied to translational research in areas such as cancer research, spatial biology, immunotherapy, and cell & gene therapy. iCura has Pennsylvania Department of Health Laboratory permit, CLIA registration, and is using CAP as its accreditation agency.
Every day, QIAGEN serves 500,000 customers globally, all seeking insights from DNA and RNA. Delivering Sample to Insight solutions for molecular testing, we help scientists and clinicians achieve breakthroughs in life sciences research, molecular diagnostics and drug development. This is how we make improvements in life possible. In healthcare and academic institutions, and drug-discovery and forensic laboratories, QIAGEN solutions advance disease detection and treatments, enable precision medicine, and aid crime detection and human identification.
Biodesix® is an experienced blood-based diagnostic solutions company with a clinical focus in lung cancer. Our comprehensive diagnostic testing capabilities help our partners decipher the complexity of cancer by profiling both the tumor and immune system. Biodesix creates end-to-end solutions with our biopharma partners from initial biomarker discovery to companion diagnostic partnering, including commercialization and reimbursement.
SensID, headquartered in Germany is specialized in the development and manufacturing of tissues with limited availability (reference materials for molecular nucleic acid diagnostics). We offer to our customers reference materials precisely characterized and manufactured in compliance with the highest standards including ISO 13485. Our continuously growing product portfolio offers ideal solution options for your R&D programs as well as assay and instrument validation requirements. They serve as external controls, support accreditation, EQA-schemes, conformity assessment, can be used for IVDR / FDA compliance and can even be supplied as OEM products to you.
For more information, please visit www.sens-id.com
BD Biosciences produces research and clinical tools for the study of single cells to better understand infectious diseases, immunological disorders and cancers. That information can aid in the discovery and development of new drugs and vaccines, including development of biomarkers and CDx, and supports the diagnosis and management of diseases. Products include the BD FACSLyric™ Flow Cytometer (RUO/IVD), BD FACSDuetTM Sample Preparation System (IVD), BD FACSymphony™ A5 Cell Analyzer and S6 Cell Sorter (RUO), BD Rhapsody™ Single-Cell Analysis System for multiomics (RUO), a comprehensive reagent portfolio (RUO/IVD) and informatics solutions with FlowJo™ Software (RUO). More solutions. More answers. More data you can trust. Discover more with BD at your side.
Rules-Based Medicine (RBM), a Q2 Solutions Company, is a CLIA certified, multiplexed immunoassay testing laboratory that solves complex drug development challenges with innovative biomarker services and a novel whole blood immunophenotyping device (TruCulture®). RBM’s internally developed and manufactured immunoassays based on Multi-Analyte Profiling (MAP) and Single-Molecule Array (SimoaTM) ultrasensitive immunoassay technology provides translational and clinical researchers with reproducible and quantitative data for a few or hundreds of human proteins. The comprehensive menu provides extensive coverage of numerous pathways and delivers accurate pharmacodynamic and safety assessments. RBM’s CLIA certified biomarker testing laboratory is located in Austin, TX.
Cureline, Inc. is a global contract research organization (CRO) and a commercial biobank supporting preclinical research in oncology, hematology, immune-oncology and various other therapeutic areas (Cardio-vascular, metabolic, neuro-degenerative, infectious and inherited conditions) to the pharmaceutical, biotechnology, and medical device industries worldwide since 2003.
